Ayal Hendel

Dr. Ayal Hendel is a Principal investigator in the Mina and Everard Goodman Faculty of Life Sciences at Bar-Ilan University (https://www.hendelab.com/). Dr. Hendel’s research focuses on developing genome editing as a curative therapy for childhood disorders and for cancer immunotherapy applications. Dr. Hendel received his BA with High Honors from the Hebrew University of Jerusalem in Biology and his MSc and PhD from the Weizmann Institute of Science with Prof. Zvi Livneh. Dr. Hendel carried out post-doctoral research with Dr. Matthew Porteus at Stanford University School of Medicine where he was part of a team that achieved therapeutically relevant genome editing frequencies in human stem cells confirming the potential of this technological breakthrough (PCT/US2016/026028 & PCT/US2016/053344). He is the Chair of the CRISPR-IL scientific committee (https://crispril.com/) and a member of the 8400 Health Network, which aims to gather leaders at the intersection of health and technology to help Israel become a life science powerhouse. He also serves as an Associate Editor in the journal Frontiers in Genome Editing. Dr. Hendel won the ERC Starting Grant, the Israel Precision Medicine Partnership (IPMP) grant of the Israel Science Foundation and his lab is part of the EDITSCD group, involving eight academic and industrial partners funded by Horizon Europe, aims at assessing the efficacy and safety of genome editing approaches for sickle cell disease.